Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer

Abstract EN

Prostate cancer is one of the most common malignancies in men.

Charles Huggins and Clarence V.

Hodges reported the androgen dependence of prostate cancer in 1941.

That led to the utilization of androgen deprivation therapy as an important therapeutic modality to treat prostate cancer.

Androgen deprivation therapy has additional systemic effects that include sexual dysfunction, psychological changes and more important are the metabolic changes.

Metabolic changes in particular include insulin resistance, increase fat mass and low-density lipoprotein cholesterol, and induce type 2 diabetes.

In this review we will focus on the cardiovascular risk associated with androgen deprivation therapy that includes the mechanisms involved.